Diabetic peripheral neuropathy (DPN) is one of the most common diabetic complications. Mechanisms underlying nerve damage and sensory loss following metabolic dysfunction remain largely unclear. Recently, hyperglycemia-induced mitochondrial dysfunction and the generation of reactive oxygen species (ROS) have gained attention as possible mechanisms of organ damage in diabetes. Hypoxia-inducible factor 1 (HIF1α) is a key transcription factor activated by hypoxia, hyperglycemia, nitric oxide as well as ROS, suggesting a fundamental role in DPN susceptibility. We analyzed regulation of HIF1α in response to prolonged hyperglycemia. Genetically modified mutant mice, which conditionally lack HIF1α in peripheral sensory neurons (SNS-HIF1α
Introduction
Diabetes is a chronic progressive metabolic disease characterized by elevated levels of blood glucose. It is one of the largest health care problems worldwide, with more than 422 million diabetic patients [1] . Diabetic peripheral neuropathy (DPN) is one of the most common diabetic complications. Patients with DPN experience pain, tingling, prickling sensations, and numbness, which can progress to complete loss of sensation and motor dysfunction. These late diabetic complications in combination with vascular damage are the leading cause of lower extremity amputations [2, 3] . Clinical research from the last two decades indicates that rigorous control of glucose reduces the incidence of DPN, suggesting a major role for hyperglycemia [4] .
Uncovering molecular mechanisms underlying DPN remains a major challenge and a lack of mechanistic understanding has long hampered effective therapy of DPN. Only recently, hyperglycemia-induced mitochondrial dysfunction and the subsequent generation of reactive oxygen species (ROS) have gained attention as possible mechanisms [5] . Prolonged hyperglycemia energizes activation of the polyol [6] , and hexosamine pathways [7] , activation of PKC isoforms [8] , and production of advanced glycation end products (AGE) [9, 10] , thereby cumulatively increasing the intracellular ratio of NADH/NAD+. It has been hypothesized that this depletion of cellular antioxidant potential leads to cellular damage, which is marked by the progression of DPN [11] . Hyperglycemia-induced ROS formation causes the development of a pseudohypoxia state, which modulates intracellular signaling pathways such as mitogen activation protein kinases (MAPKs), nuclear factor kappa B (NF-κB), activator protein I (AP-I), and importantly, hypoxia-inducible factor-1 (HIF-1) [12, 13] .
HIF1 is a heterodimeric transcriptional factor composed of α and β subunits (HIF1α and HIF1β, respectively) [14, 15] . HIF1α is an oxygen-sensitive subunit and its activity is tightly regulated by cellular oxygen concentration [15] , while HIF1β is constitutively expressed. In conditions of normoxia, HIF1α is subjected to oxygen-dependent hydroxylation at two prolyl residues, which enables its binding to the Hippel-Lindau protein (VHL) leading to polyubiquitination and subsequent proteasomal degradation [16, 17] . In contrast, under hypoxic conditions, hydroxylation of HIF1α is inhibited, resulting in accumulation of HIF1α and its heteromerization with HIF1β. In consequence, stabilized transcription factor HIF1 binds to hypoxia response elements (HREs) and regulates the expression of target genes, leading to biological consequences.
In contrast to the clarity on hypoxia-mediated modulation of HIF1α, the role of hyperglycemia in the modulation of HIF1α is subject to much debate. Previous studies report contradictory observations, e.g., hyperglycemia-induced stabilization of HIF1α in pancreatic cancer cells versus its inhibition in primary dermal fibroblasts [33, 45] . Moreover, there is no knowledge on the role of HIF1α in hyperglycemia-induced dysfunction in peripheral sensory neurons in the course of DPN. Recently, it was reported that HIF1α deletion results in exaggerated acute thermal and cold nociception [18] in naïve mice, suggesting that HIF1α activity is important in peripheral nociceptive neurons. However, to date, the role of HIF1α in pathological DPN-related structural and functional changes in peripheral sensory neurons has not been studied.
Here, we investigated the role of HIF1α in peripheral painsensing (nociceptive) neurons over the chronic progression of DPN in mice genetically lacking HIF1α conditionally in the dorsal root ganglia (DRG) by undertaking detailed longitudinal analyses spanning 6 months following induction of type1 diabetes in the streptozotocin (STZ) model. Our results uncover a previously undescribed protective role of HIF1α in nerve damage and sensory loss associated with chronic stages of DPN and lead to the surprising observation that HIF1α is an upstream modulator of ROS levels and oxidative stress in peripheral sensory neurons under diabetic conditions.
Material and methods

Animal experiments
Age-matched 7-9 week-old SNS-HIF1α −/− and HIF1α fl/fl mice were used for experiments. Animals were maintained in a temperature-controlled room with a light/dark cycle (12/ 12) . Four to five littermates were housed in individually ventilated cage-rack system (Techniplast, Italy) with free access to water and food. All animal experiments were done in accordance with ethical guidelines and approved by Regierungspräsidium Karlsruhe, Germany.
Sensory neuron-specific knockout mice
To investigate the role of HIF-1α in DPN, we employed mice lacking HIF-1α (SNS-HIF1α
) in a sensory neuron-specific manner, which were previously described by Kanngiesser et al. [18] . Briefly, mice carrying homozygous alleles of the HIF1α gene (HIF1α fl/fl ) were mated with mice expressing the Cre recombinase under the control of the sodium channel 1.8 (Na v 1.8) promoter (SNSCre) [19] , selectively in nociceptors to obtain homozygous SNS-HIF1α −/− and HIF1α fl/fl (control littermates). We have previously described the basic characterization of these mice in the study by Kanngiesser et al. [18] . To confirm the deletion of HIF-1 α, we performed the in situ mRNA hybridization on 14 μm DRG sections of SNS-HIF1α −/− and HIF1α fl/fl . Non-radioactive digoxigenin (Dig)-UTP-labeled antisense and sense probe were generated against nucleotide 1-532 of mouse HIF1α cDNA. Freshly cut DRG sections were prehybridized for 2 h at 65°C and hybridized overnight at 65°C with sense or antisense probes. Post-hybridization, the sections were washed, incubated with anti-Dig-AP (Roche Diagnostics), developed with BM purple AP substrate (Roche Diagnostics), and embedded in Mowiol.
Rodent model of type 1 diabetic model
Diabetes was induced by low-dose multiple injections of STZ (60 mg/kg/d) in citrate buffer, intraperitoneally (i.p), in 8-week-old SNS-HIF1α −/− or HIF1α fl/fl mice for 5 consecutive days. Control mice received citrate buffer injection alone (nondiabetic groups). Blood glucose levels were measured once weekly using a glucometer (Accu-Chek, Roche Diagnostics) for the entire course of the experiment. Mice above > 350 mg/dl were considered to be diabetic. Mice were analyzed over a period of 5 to 24 weeks post-STZ injection. At 2 weeks post-STZ injection, we achieved blood glucose between 380 and 500 mg/dl. The blood glucose levels were maintained in a range between 380 and 480 mg/dl by administering insulin sub-cutaneously as required over the entire course of an experiment to ensure uniformity and consistency. Insulin was not administered in mice with glucose levels of 450 mg/dl. Mice with blood glucose levels of 450-500, 500-550, and > 550 mg/dl were injected with 1, 2, and 3 units of insulin, respectively, to ensure that blood glucose levels were in the abovementioned range. Insulin was administered once a week. To avoid any trophic effects of insulin on experimental readouts, insulin was not injected for 6 days prior to behavioral analyses recording or tissue extraction.
Behavioral measurements
All behavioral experiments were done in awake, unrestrained, acclimatized, and age-matched adult mice. All experimental groups included equal number of male and female mice. Mice were habituated to the experimental setup twice a day for 4 days prior to the behavioral testing. The experimenter was blinded for both the genotype as well as to whether they received STZ or citrate injection. Thermal sensitivity was measured by recording paw withdrawal latency on application of infrared (IR) heat source on the plantar surface of the hind paw. A cut off of 20 s was set to avoid burning of tissue. Two consecutive heat applications are performed at a time interval of 5 min. Von Frey measurements were done to assess mechanical sensitivity as described previously [20] . Briefly, mice were placed on an elevated grid and von Frey monofilaments exerting a specific force of 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, 2.0, and 4.0 g were tested on the plantar hind paw. Each monofilament was applied for five times at time interval of 5 min on the plantar hind paw. Sixty percent response frequency was as Bthresholds^as described previously at basal, 14, and 24 weeks post-STZ injection.
ROS measurements in DRG
To detect production of ROS and superoxide in DRG of SNSHIF1α −/− and HIF1α fl/fl diabetic and nondiabetic mice, we intrathecally (i.t) injected MitoTracker Red CM-H 2 XROS dye (100 nm, 10 μl, Life Technologies). Twenty-four hours later, mice were perfused with 1x PBS and 4% PFA and DRG were extracted and 16-μm sections were made on cryotome [21] . The dye is in a reduced form and non-fluorescent in the basal state and becomes fluorescent upon oxidation [22] . MitoTracker Red CM-H 2 XROS fluorescence at different time points post-STZ injection was analyzed using confocal microscopy. A total of 110 cells were counted per tissue section. In total, 10 sections per mouse and 6 mice per group were included for quantifications of fluorescence intensity. The DRG sections were stained with dapi to differentiate neuronal cells from satellite cell. Quantifications were done by counting DRG cells positive for MtioTracker Red.
Immunohistochemistry
Immunohistochemistry was performed on punch biopsies of the plantar surface of the hind paws in diabetic and nondiabetic HIF1α fl/fl and SNS-HIF1α −/− mice prior to and different time points post-STZ. The mice were perfused with 4% paraformaldehyde (PFA) and plantar skin was post-fixed in 4% PFA for 24 h at 4°C. After overnight incubation in 30% sucrose, 16 μm cryo sections were made. The sections were permeabilized in 0.5% PBST, washed, and blocked with 7% horse serum (HS). The sections were incubated overnight with anti-CGRP (1:1000, sigma) or Protein Gene Product 9.5 (PGP 9.5) primary antibody in 7% HS in PBS at 4°C [23] . Subsequently, sections were washed and incubated in Alexa Fluor-594-or Alexa Fluor-488-conjugated secondary antibody. Further, the sections were washed and mounted in Mowiol. Fluorescence images were obtained using a laserscanning spectral confocal microscope and maximal projections were created using the Leica SP8 software (Leica TCS SP8 AOBS, Bensheim, Germany). Same conditions were used for imaging of sections from control and test groups. The acquired images were analyzed using the ImageJ software. Each image was converted to 8-bit and the epidermal area was marked using the region of interest (ROI) tool. Fluorescence density was calculated over the marked epidermal area after background subtraction. The experimenter was blinded to the identity of the sections that were subjected to scanning and quantification of fluorescence. 
Quantification of hydrogen peroxide in tissue
Western blot analysis
Western blots were performed on the DRG and sciatic nerve tissues extracted from diabetic and nondiabetic HIF1α fl/fl and SNS-HIF1α −/− mice. The lysates were prepared in RIPA buffer and probed with using anti-PKG1α (Cyclic GMPdependent protein kinase 1), anti-HIF1α (1:750, SigmaAldrich), anti-vascular endothelial growth factor (VEGF) (1:500, Merck Millipore), and anti-tubulin (1:6000, T2200, Sigma-Aldrich). Membranes were incubated with anti-rabbit (1:4000) or anti-mouse (1:5000) or streptavidin HRPconjugated and developed using Amersham™ ECL™ (GE Healthcare) and Hyperfilm MP (Amersham). At least three samples from independent experiments were analyzed by densitometry using Image J and corrected for loading by normalization to corresponding bands for ß-tubulin.
Statistical analysis
All the data were calculated and are presented as mean ± SEM. ANOVA for repeated measures followed by Bonferroni's test for multiple comparisons were employed to determine statistically significant differences. Changes with p ≤ 0.05 were considered to be significant.
Results
In vivo modulation of nociception by HIF1α in the STZ model of type 1 diabetes
This study investigated the role of HIF1α in the modulation of levels of ROS in dorsal root ganglia in diabetic and nondiabetic mice. In order to address a potential contribution of HIF1α to DPN, we employed a mouse line with conditional genetic loss of HIF-1α selectively in a sensory neuronspecific manner (SNS-HIF1α
) mice [18, 19] . In situ hybridization using HIF1α-specific riboprobes showed Cre/loxPmediated HIF1α deletion selectively in nociceptive sensory neurons of the DRG (Fig. 1a) . The STZ model of type 1 diabetes is characterized by slowly progressive β cell death and subsequently lymphocytic infiltration of pancreatic islets [26] . To investigate the role of HIF-1α in diabetes-induced ROS modulation, we employed a protocol of STZ injections, which gradually induces hyperglycemia and precludes acute neurotoxic effects that may result from high doses of STZ [24, 25] . Using this protocol, hyperglycemia developed to comparable levels in SNS-HIF1α −/− and HIF1α fl/fl mice (Fig. 1b) . Behavior measurements in STZ-injected mice are an important and direct measure of the progression of DPN. The STZ protocol reproduces sensory phenomena of human DPN, i.e., hyperalgesia, which is evident over 5-8 weeks post-STZ, and progressive loss of sensory functions, which is evident starting 20 weeks post-STZ injection [27, 28] . We performed longterm studies in SNS-HIF1α −/− and corresponding control mice (HIF1α
) in the STZ model to determine the course of behavioral changes, setting a focus on 5, 13, and 24 weeks post-STZ injection. Thus, the time points we chose are temporally separated from potential acute toxic effects of STZ.
At 5 weeks post-STZ, we observed that both SNS-HIF1α −/− and HIF1α fl/fl develop similar levels of hypersensitivity to mechanical stimuli applied to the plantar surface of the paw in the form of graded strength von Frey hairs, evident as a decrease in mechanical nociceptive thresholds (Fig. 1c, d) . Similarly, the development of thermal hyperalgesia which is evident as a decrease in latency to an infrared heat lamp applied to the hind paw plantar surface (Fig. 1c, d ). In contrast, at 13 and 24 weeks post-STZ injection, deletion of HIF1α in sensory neurons of the DRG had a marked impact on the development of sensory losses. Upon measuring mechanical response thresholds at 13 and 24 weeks post-STZ, we observed that SNS-HIF1α −/− showed hypoalgesia as compared to HIF1α fl/fl mice, indicating an increase in the magnitude of STZ-induced sensory losses (Fig. 1c,* , #p < 0.0001, ANOVA, Bonferroni's test). In contrast, citrate buffer-injected, age-matched littermates did not show any differences in behavioral readouts (Fig. 1e) . Similarly, in the Hargreaves test, the time required for paw withdrawal upon stimulation with radiant heat was significantly increased in STZ-treated SNS-HIF1α −/− mice as compared to STZ-treated HIF1α fl/fl mice (Fig. 1d , *p < 0.05, ***p < 0.0001, #p < 0.01, ANOVA, Bonferroni's test), whereas no differences were observed in citrate bufferinjected control animals (Fig. 1f) . The change in threshold or response time over basal measurements (Fig. 1c, d right panels, *p < 0.05, #p < 0.01, ANOVA, Bonferroni's test) with progression of diabetes indicates that SNS-HIF1α −/− mice developed faster onset of hypoalgesia and thus showed a stronger loss of sensory function as compared to control mice, this is indicative of an accelerated course of DPN upon loss of HIF1α specifically in peripheral sensory neurons.
Manifestation of DPN in SNS-HIF1α −/− mice post-STZ injection
In order to complement behavioral abnormalities with actual changes in nerve morphology, we conducted a detailed neuropathological analysis of changes in epidermal nerve fiber density. We performed immunostaining of markers for nociceptive nerves, such as calcitonin gene-related peptide (CGRP) or protein gene product 9.5 (PGP 9.5) on skin sections in a longitudinal analysis up to 24 weeks post-STZ. We analyzed DPN-associated reductions in the density of epidermal nociceptive innervation, measured by the fluorescence intensity of both CGRP-positive fibers and PGP9.5-positive fibers in the epidermal region of the glaborous skin derived from the paw. The magnitude of this loss was higher and the progression faster in SNSHIF1a −/− mice as compared to HIF1α fl/fl mice for fibers expressing CGRP (Fig. 2a, d , *p < 0.0001, #p < 0.01, ANOVA, Bonferroni's test) and fibers expressing PGP 9.5 (Fig. 2b , e * p < 0.0001, #p < 0.01, ANOVA, Bonferroni's test), at 13 and 24 weeks post-STZ injection, indicating an aggravation of DPN manifestations in the absence of HIF1α.
Modulation of ROS levels in DRGs of diabetic mice by HIF1α
Previous studies have established that hyperglycemia modulates the respiratory chain of the mitochondria and augments oxidative stress [29] . Overproduction of ROS has been shown to modulate HIF1 function [30] , with both positive and negative modulation being reported, and several mechanisms have been proposed [16, 31, 32] . Despite these insights on the regulation of HIF1 by ROS, none of the studies investigated the impact of HIF1 function on modulation of ROS levels itself. Therefore, we measured the levels of ROS in vivo in DRG neurons of SNS-HIF1α −/ − and control HIF1α fl/fl mice in the basal state (i.e., naïve mice) and at 13 or 24 weeks post-STZ treatment. We intrathecally injected MitoTracker Red CM-H 2 XROS (100 nm, 10 μl), a reporter for ROS generation [22] , and observed that STZ-induced DPN was linked to a significant increase in MitoTracker Red CM-H 2 XROS fluorescence in DRG neurons, suggesting ROS and superoxide build-up (Fig. 3a, b , *, #p < 0.0001, ANOVA, Bonferroni's test).
Importantly, the extent of ROS and superoxide accumulation was significantly increased in SNS-HIF1α −/− mice as compared to HIF1α fl/fl mice at 13 and 24 weeks of STZ injection (Fig. 3a, b) . To validate these findings, we measured the levels of H 2 O 2 in the sciatic nerve and DRG neurons of SNS-HIF1α −/− and control HIF1α fl/fl at basal and at 24 weeks post-STZ injection. Levels of H 2 O 2 were significantly increased at 24 weeks post-STZ in both the sciatic nerve and DRG tissue of SNS-HIF1α −/− as compared to control HIF1α fl/fl mice (Fig. 3c , *, #p < 0.01, ANOVA, Bonferroni's test). This indicates and confirmed that deletion of HIF1α leads to ROS and superoxide accumulation in tissue. Higher levels of H 2 O 2 are attributed to modulation of several signaling cascades resulting in genomic instability, compromised cellular function and ultimately cell death [33] . Peripheral nerve dysfunction is associated with cGMP-dependent protein kinase PKG1 and PKG2, phosphodiesterase, and cysteine-rich protein 2 modulation. ROS-mediated oxidative cysteine modification results in the dimerization and auto activation of PKG1α which is crucial for actin and myosin regulation and in regrowth and guidance of peripheral neurons after injury. We therefore investigated the impact of diabetesinduced increase in ROS and superoxide levels on the PKG1α dimerization. We found similar levels of dimerized and monomeric PKG1α in both SNS-HIF1α −/− and control 
Modulation of HIF1α expression and its downstream target genes in the diabetic state
HIF1α stabilization under hypoxia conditions is well investigated; however, the possible mechanisms underlying the effect of hyperglycemia on the modulation of HIF1α are not well understood. Hence, we analyzed the impact of hyperglycemia on the levels of HIF1α in DRGs neurons and the sciatic nerve of SNS-HIF1α −/− and control HIF1α fl/fl mice in the basal state and at 24 weeks post-STZ treatment. We found that HIF1α levels in the peripheral component of the pain pathways increased with prolonged hyperglycemia (Fig. 3e, *, 
Discussion
The main insights revealed by this study are: (i) the transcription factor HIF1α plays a protective role against axonal pathology and loss of peripheral nerve fibers in DPN by inducing expression of VEGF, (ii) a loss of HIF1α in sensory neurons of diabetic mice leads to a faster progression of 
*
HIF1α has only recently been suggested to modulate pain following direct mechanical injury to peripheral nerves [18] . However, to date, nothing was known about the role of HIF1α in pain and nerve damage caused by metabolic dysfunction. Indeed, there is a large mechanistic diversity between diverse forms of pathological pain, such as that arising from direct mechanical injury to nerves that is focal and localized versus metabolically induced nerve dysfunction in the course of diabetes, which is widespread and diffuse. Very little is known about how nerve damage develops under metabolic stress. We hypothesized that HIF1α may be a vital link because it has been reported to be directly regulated by hyperglycemia in some tissues, such as endothelial cells and cardiac myocytes, with both positive and negative modulation being reported [35] . Indeed, using highly selective genetic perturbations, we observed that both structural remodeling of nerves and their functionality (via behavioral analysis) were highly affected upon a loss of HIF1α in sensory neurons. Interestingly, only chronic changes, such as structural damage and the ensuing sensory loss at about 4-6 months post-diabetes induction, were affected in SNS-HIF1α −/− mice, emphasizing the strength of longitudinal analyses. Particularly, this late component of diabetic changes is key in the clinical situation, frequently resulting in small and large fiber neuropathies, diabetic feet, and amputations [36] . In contrast, early STZevoked hypersensitivity was not changed upon a loss of HIF1α in sensory neurons. Several recent studies have addressed mechanisms of early hyperalgesia in diabetic models, and there is converging evidence that this involves acute modulation of ion-channels, such as members of the transient receptor potential (TRP) family, such as TRPV1 and TRPA1 by oxidative or lipid metabolites [37, 38] . The nature of modulation of DPN by HIF1α is of much interest. In terms of injury induced by hypoxia and/or hyperglycemia, both protective and destructive roles have been observed for HIF1α depending upon the type of tissue and the context [35, 39] . Here, we observed a protective function for HIF1α against nerve damage induced by metabolic dysfunction in a model of type 1 diabetes. DPN is manifested by increased levels of ROS and increased oxidative stress. ROS such as H 2 O 2 and hydroxyl radicals modify structural proteins, nucleic acids, and membrane lipids which are essential for maintaining neuronal health. We found increased H 2 O 2 concentration and levels of dimerized PKG1α in the DRG of diabetic mice are an indication of redox imbalance. It revealed that the deletion of HIF1α results in increased accumulation of ROS in sensory neurons as compared to controls over chronic phases of diabetes. This is unexpected because previously published studies in other tissues reported the modulation of HIF1α activity by ROS, but there is little evidence for modulation of ROS levels by HIF1α. In kidney tissue under hyperglycemia conditions, ROS has been shown to impair HIF1α activation as well as expression via inhibition of NO and Rac1 [35] . Moreover, ROS can further inhibit HIF1α by increasing ubiquitin-proteasome activity [40] . In contrast, Bonello et al. demonstrate that ROS leads to HIFα expression and activation in a NF-κB-dependent manner in pulmonary artery smooth muscle cells [41] . Indeed, we observed an increase in the expression of HIF1α in sensory neurons of chronically hyperglycemic mice. Our results indicate that ROS is downstream of HIFα, which suggests that HIFα exerts its neuroprotective functions in this context by suppressing ROS.
The precise mechanisms how HIF1α affects ROS levels are not clarified in this study. However, we attempt to study the HIF1α neuroprotective function by investigating the changes in levels of VEGF which is a known transcriptional target of HIFα [34] . Clinical studies reported an increase in plasma levels of VEGF in the diabetic patients [42] . Gene transfer studies in diabetic rats showed that VEGF restores nerve blood flow by inducing angiogenesis in the peripheral nerves and may promote peripheral nerve survival [43] . Our findings on impaired VEGF expression in diabetic SNS-HIF1α −/− mice suggests that VEGF-induced neuroprotection is lost in SNS-HIF1α −/− mice, resulting in the accelerated DPN. However, several other mechanisms may also contribute mechanistically to the protective function of HIF1α, including modulation of metabolic enzymes expression [44] , which may decrease metabolic overload in sensory nerves and suppress the generation of harmful ROS and free radical species. Recent studies have implicated ROS in the modulation of acute pain [45] , and the administration of ROS scavengers peripherally or spinally has antinociceptive effects in models of inflammatory and neuropathic pain [46] . It is believed that ROS production via the mitochondrial respiratory chain is a causal link between hyperglycemia and pathways involved in hyperglycemia-induced tissue damage. Under hyperglycemic . Prior to quantification, the input amounts were normalized to tubulin (n = 4 mice). *p < 0.05 compared to baseline, #p < 0.05 as compared to the control group two-way ANOVA for repeated measurements with Bonferroni multiple comparison test. Scale bar represents 30 μm conditions, the increased electron flux in the respiratory chain leads to an increase in the ATP/ADP ratio and in the mitochondrial membrane potential, which result in partial inhibition of complex III and thereby induce an accumulation of electrons to generate potentially harmful complex-I ROS [29, 47] . It is postulated that accumulation of ROS may result in a bioenergetic failure, depletion of antioxidant defenses, and neuroinflammation [48] . These mechanisms likely contribute to nerve damage and the ensuing sensory loss observed upon the excessive accumulation of ROS in diabetic mice lacking HIF1α.
Conclusions
In summary, this study identifies HIF1α as an important protective molecule against DPN-associated long-term nerve damage and sensory loss. Moreover, we propose that HIF1α functions as an upstream suppressor of ROS levels in sensory neurons. These observations have direct relevance to a highly debilitating and intractable long-term complication of diabetes and hold significance for novel therapeutic measures designed to strengthen the protective role of HIF1α in sensory neurons over chronic diabetes. Authors contributions NA and RK designed the study; IT mated HIF1α fl/fl mice and SNS-Cre mice and gave general conceptual input; DRR performed and analyzed in vivo experiments; NA and DRR performed and analyzed in vitro experiments; NA and RK generated the SNS-Cre line and wrote the manuscript. All authors approved the final version.
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